The FDA decision on MacroGenics Inc.’s (MGNX) Margetuximab, proposed for the treatment of patients with pre-treated metastatic HER2-positive breast cancer, in combination with chemotherapy, is expected on December 18.Margetuximab is an Fc-engineered, monoclonal antibody that targets the HER2 oncoprotein. HER2 is expressed by tumor cells in breast, gastroesophageal and other solid tumors.In a pivotal phase III trial, dubbed SOPHIA, there was a 24% decrease in the risk of disease progression or death in patients with advanced pretreated HER2-positive metastatic breast cancer treated with Margetuximab plus chemotherapy compared to those treated with Herceptin plus chemotherapy.Roche’s Herceptin is the standard of care for HER2-positive locally advanced/metastatic breast cancer and gastric/gastroesophageal junction (GEJ) cancer.MGNX closed Friday’s (Nov.27, 2020) trading at $23.07, up 1.01%.